Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 294

Results For "UST"

4813 News Found

Advent International to acquire a significant stake in Suven Pharmaceuticals
News | December 26, 2022

Advent International to acquire a significant stake in Suven Pharmaceuticals

Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.


Searchlight Pharma to acquire Miravo Healthcare
News | December 26, 2022

Searchlight Pharma to acquire Miravo Healthcare

Miravo to remain a Canadian controlled and operated company following closing of the transaction


Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes
News | December 22, 2022

Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes

This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation


Vaishali Pharma signs partnership agreement with Jark Pharma
News | December 22, 2022

Vaishali Pharma signs partnership agreement with Jark Pharma

As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products


Indira IVF forays into diagnostic business with ‘Indira Pathlabs’
News | December 21, 2022

Indira IVF forays into diagnostic business with ‘Indira Pathlabs’

Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients


Cadila Pharmaceuticals appoints Ashraf Allam as Global COO
People | December 20, 2022

Cadila Pharmaceuticals appoints Ashraf Allam as Global COO

Allam was serving recently as the CEO at Public Investment Fund


Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData
Healthcare | December 20, 2022

Diabetic neuropathic pain field presents significant opportunity for drug developers, says GlobalData

36.4% of patients with diabetic neuropathic pain in 2021 were completely treatment refractory and would benefit from new treatment options.